<DOC>
	<DOCNO>NCT00459004</DOCNO>
	<brief_summary>The primary objective verify dose-response relationship rimonabant body weight change . The secondary objective compare effect 3 dos SR141716 placebo , body weight loss secondary criterion associate comorbidities , evaluate safety pharmacokinetics SR141716 .</brief_summary>
	<brief_title>Japanese Dose-Response Study Rimonabant Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Body Mass Index ≥25 kg/m² Viceral Fat Area ≥ 100 cm² Diet therapy 8 week start placebo observation period Stable weight ( variation &lt; ±3kg within 8 week start observation period ) At least 2 criterion follow 3 comorbidities : Impaired Glucose Tolerance Type 2 diabetes , Dyslipidemia ( hypertriglyceridemia and/or low HDLchoresterol ) , Hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>weight loss</keyword>
</DOC>